Search research articles
Contact Us
Filters
Showing results (161-170 of 174) with videos related to
Page
of 18
Sort By:
ACS Medicinal Chemistry Letters
|
September 17, 2021
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis
Joseph Carpenter, Gang Wu, Ying Wang, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 18, 2004
Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists
Jeffrey G Varnes, Daniel S Gardner, Joseph B Santella, et al.
Eclinicalmedicine
|
July 1, 2021
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
Michael A Puskarich, Nathan W Cummins, Nicholas E Ingraham, et al.
Journal of Medicinal Chemistry
|
February 24, 2007
Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor
Dean A Wacker, Jeffrey G Varnes, Sarah E Malmstrom, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis
Joseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 18, 2002
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships
Dean A Wacker, Joseph B Santella, Daniel S Gardner, et al.
JAMA Network Open
|
March 16, 2022
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial
Michael A Puskarich, Nicholas E Ingraham, Lisa H Merck, et al.
Journal of Medicinal Chemistry
|
June 15, 2022
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis
Susheel J Nara, Srinivas Jogi, Srinivas Cheruku, et al.
Biomolecular NMR Assignments
|
November 7, 2020
<sup>1</sup>H, <sup>13</sup>C, and <sup>15</sup>N backbone chemical shift assignments of coronavirus-2 non-structural protein Nsp10
N Kubatova, N S Qureshi, N Altincekic, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency
George V De Lucca, Ui Tae Kim, Brian J Vargo, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 174) with videos related to
Sort By:
Page
of 18
ACS Medicinal Chemistry Letters
|
September 17, 2021
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis
Joseph Carpenter, Gang Wu, Ying Wang, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 18, 2004
Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists
Jeffrey G Varnes, Daniel S Gardner, Joseph B Santella, et al.
Eclinicalmedicine
|
July 1, 2021
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19
Michael A Puskarich, Nathan W Cummins, Nicholas E Ingraham, et al.
Journal of Medicinal Chemistry
|
February 24, 2007
Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor
Dean A Wacker, Jeffrey G Varnes, Sarah E Malmstrom, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 22, 2007
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis
Joseph B Santella, Daniel S Gardner, Wenqing Yao, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 18, 2002
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships
Dean A Wacker, Joseph B Santella, Daniel S Gardner, et al.
JAMA Network Open
|
March 16, 2022
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial
Michael A Puskarich, Nicholas E Ingraham, Lisa H Merck, et al.
Journal of Medicinal Chemistry
|
June 15, 2022
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis
Susheel J Nara, Srinivas Jogi, Srinivas Cheruku, et al.
Biomolecular NMR Assignments
|
November 7, 2020
<sup>1</sup>H, <sup>13</sup>C, and <sup>15</sup>N backbone chemical shift assignments of coronavirus-2 non-structural protein Nsp10
N Kubatova, N S Qureshi, N Altincekic, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency
George V De Lucca, Ui Tae Kim, Brian J Vargo, et al.
Page
of 18